



## **TCR² Therapeutics to Present at the Truist Securities Life Sciences Summit**

April 29, 2021

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021 at 11:20am E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company's website at [www.investors.tcr2.com](http://www.investors.tcr2.com). An archived replay will be available for at least 30 days following the presentation.

### **About TCR² Therapeutics**

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²'s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company's lead TRuC-T cell product candidate targeting solid tumors, gavo-cel, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company's lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit [www.tcr2.com](http://www.tcr2.com).

### **Investor and Media Contact:**

Carl Mauch  
Director, Investor Relations and Corporate Communications  
TCR² Therapeutics Inc.  
(617) 949-5667  
[carl.mauch@tcr2.com](mailto:carl.mauch@tcr2.com)



Source: TCR² Therapeutics